The Global Rituximab Biosimilars Market Report by The Business Research Company covers rituximab biosimilars market drivers and restraints, rituximab biosimilars market size, major players, and the impact of COVID-19 on the rituximab biosimilars market.
The rituximab biosimilars market consists of sales of rituximab biosimilars. Biosimilars are pharmaceuticals that are manufactured using cell lines and are similar to biologics. Rituximab biosimilars are used as a single agent or in combination with chemotherapy for the treatment of various diseases including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), microscopic polyangiitis (MPA), and granulomatosis with polyangiitis (GPA).
The rising prevalence of non-Hodgkin’s lymphoma (NHL) is predicted to contribute to the growth of the rituximab biosimilars market.
The global rituximab biosimilars market is expected to grow from $1.75 billion in 2020 to $1.9 billion in 2021 at a compound annual growth rate (CAGR) of 8.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The rituximab biosimilars market is expected to reach $3.02 billion in 2025 at a CAGR of 12%.
Request A Sample For The Global Rituximab Biosimilars Market Report:
Some rituximab biosimilars market trends include the companies operating in the biosimilars continuously focusing on new product development in collaborations with other companies operating in the industry. Innovations through partnerships are shaping the rituximab biosimilars market.
Global rituximab biosimilars market segments include:
1) By Application: Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukaemia, Rheumatoid Arthritis, Others.
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Direct Distribution Channels.
3) By Route Of Administration: Subcutaneous, Intravenous, Molecular Type.
By Geography: The market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.
Read More On The Rituximab Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030 At:
The Rituximab Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides rituximab biosimilars market overviews, analyzes and forecasts market size, share, rituximab biosimilars market players, rituximab biosimilars market segments and geographies, market’s leading competitors’ revenues, profiles and market shares.
The rituximab biosimilars market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Where To Learn More:
Read Rituximab Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030 from The Business Research Company for information on the following:
Data Segmentations: Market Size, Global, By Region And By Country, Historic And Forecast Size, And Growth Rates For The World, 7 Regions And 12 Countries.
Market Players Covered: Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co. Ltd., Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Ko. KG, BioXpress Therapeutics SA, Intas Biopharmaceuticals Ltd.
Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Time Series: Five years historic (2015-20) and ten years forecast (2021-2025-2030)
Other Information And Analyses: SWOT analysis, customer information, market product/service analysis – product examples, trends and opportunities, drivers and restraints, key mergers and acquisitions, suggested trend based strategies, impact of COVID-19 on the market, future outlook and potential analysis, key metrics covered: number of enterprises, number of employees, global market in 2021 – countries offering most new opportunities, conclusions and recommendations by expert analysts.
Sourcing And Referencing: Data and analysis throughout the report are sourced using end notes.
Strategies For Participants In The rituximab biosimilars Industry: The report explains a number of strategies for companies in the market, based on industry trends and company analysis.
Opportunities For Companies In The rituximab biosimilars Sector: The report reveals where the global industry will put on most $ sales up to 2023.
Interested to know more about The Business Research Company?
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
Here is a list of reports from The Business Research Company similar to the Rituximab Biosimilars Global Market Report 2021: